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Abstract. Background: Breast cancer patients are at
increased risk of osteoporosis. Contributing factors include age
and/or chemotherapy. The selective estrogen modulator,
raloxifene (RAL), effective in the prevention of breast cancer
and approved for the treatment and prevention of
osteoporosis, may prove beneficial in current breast cancer
treatment modules. The purpose of this study was to evaluate
RAL in combination with 5-fluorouracil (5-FU) and
trimetrexate (TMX) to determine the most effective sequence
in which to administer these cell cycle specific agents while
taking into consideration the cellular mechanism of action.
The goal was to maintain cytotoxicity to breast cancer cells
and capitalize on the selective estrogen receptor modulatory
effects of RAL. Materials and Methods: MCF-7 cells were
exposed to (i) TMX, 5-FU or RAL alone, or (ii) RAL 24 h
prior to 5-FU followed 2 h later by TMX, or (iii) 5-FU 2 h
prior to TMX followed 24 h later by RAL. The cell viability
was determined using the Quick Cell Proliferation Assay.
Results: The growth rate of MCF-7 cells exposed to early RAL
was 68.25±4.11% that of the control, however, late RAL
exposure produced a growth of 34.75±4.79% that of the
control. Late RAL maintained the cytotoxicity of the regimen.
The findings were further supported by cell flow cytometry and
Western blot analysis data. Conclusion: RAL given prior to 
5-FU/TMX significantly compromised cytotoxicity to breast
cancer cells. 
The selective estrogen receptor modulator (SERM)
raloxifene (RAL), which binds to and selectively inhibits
the estrogen receptor, is used for the prevention and
treatment of osteoporosis (1-3). RAL is not only effective
in the prevention of breast cancer (4, 5) but has also been
shown to be as effective in breast cancer prevention as
the prototype SERM, tamoxifen (6). The ability of RAL
to treat osteoporosis and its selective antiestrogen
properties could be especially beneficial to the
postmenopausal breast cancer patient. Postmenopausal
survivors of breast cancer are at increased risk of low
bone mineral density (BMD), increased fractures and
ultimately osteoporosis (7). Incorporating RAL into
existing, effective antineoplastic combinations may
improve the prognosis of the node- positive breast cancer
patient; however, RAL in combination with other
antineoplastic agents has not been extensively studied in
breast cancer. A breast cancer treatment regimen of
interest used in the clinic consists of the classic antifolate
methotrexate (MTX) and the fluoropyrimidine, 5-
fluorouracil (5-FU). 5-FU is administered prior to MTX
and selective antifolates to diminish cytotoxicity to bone
marrow while maintaining cytoxicity to breast cancer cells
(8-11). Previously, this laboratory has shown that the
sequence of RAL administration, relative to MTX, can
affect the overall cytotoxicity to proliferating breast
cancer cells (12, 13). The lipid soluble antifolate
trimetrexate (TMX) is used when breast cancer cells
become MTX-resistant. 
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RAL arrests cells in the G1-phase of the cell cycle. 5-FU
and TMX arrest cells in the S-phase of the cell cycle.
Because RAL and the antimetabolites 5-FU and TMX
target different phases of the cell cycle and exhibit different
mechanisms of action and clinical toxicity, we investigated
the in vitro effects of the sequence of their administration
on the growth of MCF-7 human breast cancer cells.
Materials and Methods
Cell viability assays: ·ssessment of cell viability by manual cell counting.
MCF-7 cells were obtained from the American Type Tissue Culture
(Manassas, VA, USA). Trimetrexate glucuronate was obtained from
US Bioscience Inc., West Conshohocken, PA, USA. 5-FU and RAL
were purchased from Sigma (St. Louis, MO, USA). Stock cultures
of MCF-7 cells were grown in 150 cm3 flasks and incubated in
RPMI-1640 media (Cellgro, Mediatech Inc., VA, USA). For each
experiment, 1x106 cells were plated in 100 mm tissue culture Petri-
dishes. After 24 h incubation in a humidified atmosphere of 5% CO2
at 37ÆC, with the exception of an untreated control group, cells in
each of five 100 mm Petri dishes were exposed to (i) 10 ÌM TMX, 1
ÌM 5-FU, 10 ÌM RAL alone, (ii) 10 ÌM RAL 24 h prior to 1 ÌM 5-
FU followed 2 h later by 10 ÌM TMX (early RAL combination), or
(iii) 1 ÌM 5-FU 2 h prior to 10 ÌM TMX followed 24 h later by 10
ÌM RAL (late RAL combination). Following 48 h of exposure, cells
were harvested. The viability of cells was determined by microscopic
counting of the Trypan blue exposed cells with a hemocytometer.
Assessment of cell viability using the Quick Cell Proliferation Assay.
Additional cell viability studies were performed using the automated
Quick Cell Proliferation Assay (BioVision Research Products,
Mountain View, CA, USA) to complement the Trypan blue dye
exclusion assay. MCF-7 cells (1.5x104 cells) were exposed to the
previously mentioned drugs as described above. Following 48 h of
exposure, 10 ÌL of WST-1/ECS solution was added and to the cells
which were incubated for an additional 4 h at 37ÆC in a humidified
atmosphere of 5% CO2. The assay was stopped by adding 10 ÌL of
1% SDS into each well and shaking thoroughly. The formazan dye
produced by viable cells was quantified by measuring the absorbance
of the dye solution at 440 nm using a microtiter plate reader. The
percent viability was calculated comparing the absorbance of treated
cells to the control (corresponding to 100% viable cells). 
Cell flow cytometry analysis. Upon completion of cell viability assays,
cells were prepared for cell flow cytometric analysis using a FITC
(fluorescein isothiocyanate) BrdU Flow Kit from BD Biosciences
Pharmingen (San Diego CA, USA). Cells were rinsed in 5 mL of 1x
DPBS (Dulbecco’s phosphate-buffered saline), trypsinized, stained
with the Trypan blue and counted. After placing 8x105 cells in 5 mL
centrifuge tubes, cells were centrifuged at 300 xg for 5 min in 1 mL of
staining buffer. The cell pellets were resuspended in 100 ÌL of
cytofix/cytoperm buffer containing 4% formaldehyde. Following a 30-
min fixation and permeabilization at room temperature, cells were
washed and centrifuged as before at 4ÆC with wash buffer containing
FBS. The cell pellets were permeabilized a second time. Staining was
enhanced by incubating the samples for 10 min on ice with 100 ÌL of
a 10% DMSO solution. After washing and centrifugation, the cell
pellet was refixed via resuspension in 100 ÌL of cytofix/cytoperm
buffer and incubated for 5 min. Cells were washed, centrifuged as
before and treated with 30 Ìg of DNase for 1 h at 37ÆC to expose
incorporated BrdU. Following DNase treatment cells were washed,
centrifuged, resuspended in 1 mL of wash buffer, and stored at 4ÆC
overnight. Twenty-four hours later, cell samples were centrifuged at
300 xg for 5 min as before. The cell pellets were resuspended in 50
ÌL of fluorochrome-conjugated anti-BrdU antibody and incubated at
room temperature for 20 min. The cell pellets were washed,
centrifuged, resuspended in 1 mL of staining buffer and analyzed with
a BD FACScan cell flow cytometer (Becton Dickinson Italia).
Western blot analysis. Twenty Ìg of protein, as measured using BCA
protein assay with bovine serum albumin as standard was isolated from
MCF-7 cells and loaded onto a 7.5% SDS gel. Following SDS-PAGE
separation, protein was transferred to a PVDF membrane, exposed to
primary antibody (mouse anti-human retinoblastoma protein Rb
monoclonal antibody 1:1000), followed by horseradish peroxidase-
conjugated secondary antibody (goat anti-mouse IgG, 1:10,000).
Antibody detection was performed using enhanced chemiluminescent
reagents Super Signal West Dura. The membrane was exposed to
Hyperfilm MP (Amersham Biosciences UK Ltd., Buckinghamshire,
Little Chalfont, UK) and developed using Kodak GBX developer and
fixer. Densitometric analysis was conducted using an AIS densitometric
computer based Imaging System (Imaging Research Inc., Canada) to
quantify the intensity of bands from five independent Western blots.
Statistical analyses. Data were expressed as mean±standard error.
Statistical differences within and between treatment groups were
determined in the MCF-7 cell line by one-way ANOVA followed
by Newman-Keuls multiple comparison test. p<0.05 was
considered statistically significant. Data were analyzed for both
control and treatment groups using Graphpad Prism 3 (Graphpad
Software, Inc., San Diego, CA, USA). 
Results
Effects of TMX, 5-FU and RAL on the proliferation of MCF-7
human breast cancer cells. The growth rate of MCF-7 cells
exposed to TMX, 5-FU or RAL alone was 39.75±6.24%,
82.0±12.09% and 63.0±8.04% that of the control,
respectively. The growth rate for early RAL was 68.25±4.11%
and for late RAL 34.75±4.79% that of the control. Late RAL
showed more cytotoxicity than early RAL and also showed a
significant reduction when compared to the control. These
results were supported by the direct cell counts using the
Trypan blue dye exclusion method and Quick Cell
Proliferation assay (Figure 1A and B). 
Effects of RAL, 5-FU, and TMX on cellular progression to the
S-phase of the cell cycle. Cell flow cytometry was used to
determine the effect of RAL on the progression of cells when
exposed to S-phase agents; the above-mentioned treatment
groups were analyzed. The cell cycle profile in (Figure 2A) is
representative of five independent experiments using the six
treatment groups. Early RAL administration corresponded
with less cytotoxicity and fewer cells entering the S-phase of
the cell cycle when compared to late RAL, which
corresponded with greater cytotoxicity and an increased
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Figure 1. The sequence-dependent interaction between TMX, 5-FU and RAL on the proliferation of human breast cancer MCF-7 cells. Cells were
exposed to (i) 10 ÌM TMX, 1 ÌM 5-FU or 10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by TMX, or (iii) 5-FU 2 h prior to TMX
followed 24 h later by RAL. Total time of exposure was 48 h. A: Cell number was counted using the Trypan blue dye. B: Viability of cells was determined
by the Quick Cell Proliferation assay. Results represent mean±SEM of five independent experiments. Analysis of variance indicated a significant reduction
compared with control (*p<0.05, **p<0.01, ***p<0.001), compared with RAL (+p<0.05, ++p<0.01, +++p<0.001), and early RAL compared with
late RAL (ññp<0.01, ñññp<0.001).
number of cells entering the S-phase of the cell cycle (Figure
2B). Late RAL showed significant increase of cells progressing
to the S-phase compared to RAL alone and the early RAL
combination.
Western blot analysis. The retinoblastoma protein (Rb), a
cell cycle regulator which when phosphorylated allows the
progression of cells from the G1- to the S-phase, was used as
a marker to determine the effects of early RAL and late
ANTICANCER RESEARCH 27: 1393-1400 (2007)
1396
Figure 2. The sequence-dependent interaction between TMX, 5-FU and RAL on the cell cycle progression of human breast cancer MCF-7 cells. Cells were
exposed to (i) 10 ÌM TMX, 1 ÌM 5-FU or 10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by TMX, or (iii) 5-FU 2 h prior to TMX
followed 24 h later by RAL. A: The cell cycle profile is representative of four independent experiments. B: Percent of cells in S-phase. Analysis of variance
indicated a significant increase compared with control (*p<0.05), compared with RAL (+p<0.05, ++p<0.01, +++p<0.001) and early RAL compared
with late RAL (ñp<0.05).
RAL on cellular progression at the molecular level. The
Western blot (Figure 3A) is representative of five
independent experiments using the six treatment groups.
The relative optical density (ROD) is shown in (Figure 3B).
The optical density of the late RAL treatment group was
significantly greater than the early RAL treatment group,
an indication of enhanced cellular progression to the S-
phase of the cell cycle and greater phosphorylation. This
observation corresponds with cell flow cytometry data which
showed significantly fewer cells entering the S-phase of the
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Figure 3. Effect of TMX, 5-FU and RAL on the level of retinoblastoma protein (Rb) as phosphorylated protein marker in human breast cancer MCF-7
cells. Cells were exposed to (i) 10 ÌM TMX, 1 ÌM 5-FU or 10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by TMX, or (iii) 5-FU 2 h
prior to TMX followed 24 h later by RAL. A: The gel image is the representative of five independent experiments. B: Relative optical density. Analysis of
variance indicated a significant increase compared with control (*p<0.05, ***p<0.001), compared with RAL (+++p<0.001). 
cell cycle for RAL alone and early RAL in combination with
5-FU and TMX than when RAL was administered last
preceded by 5-FU and TMX.
Discussion
The goal of this study was to determine if RAL could
effectively be included in antifolate/fluoropyrimidine
combination chemotherapy for the treatment of breast
cancer, as well as to illustrate the relationship between the
cytotoxicity of selective cell cycle specific agents and the
sequence in which they are administrated. 
MCF-7 human breast cancer cells were assayed for viability
to determine the cytotoxic effects of TMX, 5-FU, and RAL
alone and in combination. Results showed early RAL was
less cytotoxic to breast cancer cells than late RAL. Late RAL
administration, preceded by 5-FU and TMX, exhibited
enhanced cytotoxicity compared to RAL administration
alone. The late RAL combination, due to greater cytotoxicity,
is a more desirable combination for treating breast cancer
than RAL alone or the early RAL regimen. 
Cells exposed to TMX alone were one-half as viable as the
control in this study. The early RAL combination did not
demonstrate additive, enhanced, or synergistic cytotoxicity
when compared to TMX alone. TMX alone and the late RAL
combination were not significantly different. The early RAL
combination appears to mask TMX cytotoxicity, which is
manifested when RAL administration is reversed. In addition
to the effect of late RAL on breast cancer cells, there may be
several benefits of incorporating RAL into a 5-FU/TMX
regimen such as the promotion of bone mineral density with
RAL which will be discussed in further detail later. 
The mechanism of early RAL attenuation of 5-FU/TMX
cytotoxicity became evident via cell flow cytometric
experiments. RAL, like tamoxifen, (14) arrests cells in the
G1-phase of the cell cycle. 5-FU and TMX exert their
effects on the S-phase of the cell cycle. RAL alone inhibited
the progression of cells from the G1-phase of the cell cycle
to the S-phase, in some cases by nearly 80%. Early RAL
brought about a significant reduction in G1- to S-phase
cellular progression when compared to the late RAL
combination. When comparing early RAL and late RAL,
the percent of cells entering the S-phase of the cell cycle
was proportional to the cytotoxicity to breast cancer cells.
Evaluating their effects on the phosphorylation of the Rb
protein further elucidated the effects of the early RAL and
late RAL combinations. Rb is a cell cycle regulating protein
that exerts its effects during the early portion of the 
G1-phase. Rb in its underphosphorylated state prevents the
progression of cells from the G1- to the S-phase. Following
phosphorylation, cells commit to progression through the
remaining cycle (15). Cells that lack the Rb protein contain
inactivated Rb or alterations in the Rb activation pathway
and will enter the S-phase without regulation from Rb, as
evident in numerous tumors including retinoblastoma,
cervical carcinomas, esophageal and breast cancer (15).
Analysis of Western blot studies illustrated the effect of
early RAL and late RAL on the phosphorylation of Rb.
Early RAL in combination with 5-FU and TMX caused less
Rb phosphorylation than late RAL, providing further
insight into the mechanism of action of early RAL
attenuation of 5-FU/TMX at the molecular level.
The addition of RAL to a 5-FU and TMX regimen, based
on the time of exposure used in this study, did not
demonstrate an antineoplastic advantage over TMX alone.
The utilization of RAL in a regimen inclusive of 5-FU and
TMX to treat breast cancer will require further investigation
however; we have shown in the present study that a regimen
consisting of RAL followed by 5-FU and TMX is
significantly cytotoxic to breast cancer cells. In addition to
its toxico-therapeutic effects in the breast cancer patient
when used in combination with 5-FU and TMX, RAL could
be useful in a 5-FU/TMX regimen for patients undergoing
treatment for breast cancer who are also at risk of
developing osteoporosis. According to the National
Institutes of Health Osteoporosis and Related Bone
Diseases National Resource Center (NIH ORBD NRC), the
majority of breast cancers occur in women in their fifties.
The risk of breast cancer increases with age (16). This age
group overlaps with a growing population at increased risk
of developing osteoporosis. The National Osteoporosis
Foundation estimates that osteoporosis is a major threat for
55% of people at 50 years of age and older. Postmenopausal
breast cancer survivors are also at increased risk of
osteoporosis (7). Breast cancer treatment can decrease
circulating estrogen and induce early menopause for many
premenopausal patients. These patients could benefit from
the estrogenic bone density promoting properties of RAL.
Data from this study postulates that the sequence in which
RAL is incorporated into existing effective antineoplastic
therapies is very important. The pharmacokinetic properties
of RAL must be taken into consideration before its inclusion
in existing antineoplastic therapies in vivo. Raloxifene has
been reported to have poor bioavailability (17). Similar
studies will need to be conducted in vivo to fully ascertain the
benefits of RAL incorporation into breast cancer treatment.
However, if findings from this study are representative of the
effect of RAL on 5-FU and TMX and their treatment of the
breast cancer patient, the administration of RAL should
follow a 5-FU/TMX regimen or the cytotoxicity of 5-
FU/TMX may be compromised. This observation is not
limited to 5-FU/TMX and may also be extrapolated to other
antineoplastic agents specific for the S-phase. The
observations from this study have important implications
regarding therapeutic dosing schedules of antifolates in
combination with 5-FU and RAL in the clinical setting.
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